BridgeBio Pharma valuation
$78.30Change from previous close: +0.17%Absolute change: +$0.13
Valuation
The average price target of 20 analysts is $106.85.
Data as of November 15, 2026
BridgeBio Pharma compared with similar companies
| Metric | BridgeBio Pharma | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| Price/sales | 16.1 | 7.76 | 4.89 – 9.50 | High |
| Gross margin | 94.3% | 77.3% | 71.1% – 91.7% | High |
| Operating margin | -37.3% | 19.5% | -12.6% – 29.2% | Low |
| Net margin | -59.8% | 4.4% | -12.9% – 31.2% | Low |
| ROE | 32.8% | 8.3% | -4.2% – 88.3% | Middle |
| Debt/equity | -1.35 | 0.30 | 0.06 – 0.75 | Low |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Other metrics
Valuation multiples
- Market cap
- $15.25B
- Enterprise value
- $18.04B
- P/E (trailing 12 months)
- -19.9
- Forward P/E
- -286.5
- Price/book
- -5.17
- EV/EBITDA
- -51.8
- EV/revenue
- 19.1
Profitability and growth
- ROA
- -14.0%
- ROIC
- -63.1%
- Revenue growth (year over year)
- 192.6%
- Earnings growth (year over year)
- -18.6%
Financial health
- Total cash
- $1.54B
- Total debt
- $3.38B
- Current ratio
- 2.09
- Quick ratio
- 1.96
- Altman Z-Score
- -0.04
- Piotroski F-Score
- 2.00
Dividends
- Dividend yield
- 0.0%
Analysts and estimates
- Average price target
- $106.85
- Median price target
- $107.50
- High price target
- $156.00
- Low price target
- $80.00
- Analysts with a price target
- 20
- Consensus
- Strong buy
- Forward EPS
- -$0.27
- EPS estimate, current year
- -$2.49
Shares and trading
- Beta
- 0.94
- Average volume
- 2.69M
- Shares outstanding
- 194.8M
- Float
- 163M
- Institutional ownership
- 98.9%
- Insider ownership
- 5.0%
- Short interest (% of float)
- 12.0%
- Short ratio (days)
- 7.35
